The 2013 Cholesterol Guideline Controversy: Would Better Evidence Prevent Pharmaceuticalization?
Keywords
Cardiovascular disease; Cholesterol guidelines; Clinical guidelines; Conflict of interest; Lifestyle changes; Pharmaceuticalization
Abstract
Cardiovascular disease (CVD) remains the leading cause of death globally. A class of medications, known as statins, lowers low-density lipoprotein cholesterol levels, which are associated with CVD. The newest 2013 U.S. cholesterol guideline contains an assessment of risk that greatly expands the number of individuals without CVD for whom statins are recommended. Other countries are also moving in this direction. This article examines the controversy surrounding these guidelines using the 2013 cholesterol guidelines as a case study of broader trends in clinical guidelines to use a narrow evidence base, expand the boundaries of disease and overemphasize pharmaceutical treatment. We find that the recommendation in the 2013 cholesterol guidelines to initiate statins in individuals with a lower risk of CVD is controversial and there is much disagreement on whether there is evidence for the guideline change. We note that, in general, clinical guidelines may use evidence that has a number of biases, are subject to conflicts of interest at multiple levels, and often do not include unpublished research. Further, guidelines may contribute to the “medicalization” or “pharmaceuticalization” of healthcare. Specific policy recommendations to improve clinical guidelines are indicated: these include improving the evidence base, establishing a public registry of all results, including unpublished ones, and freeing the research process from pharmaceutical sector control.
Publication Date
7-1-2016
Publication Title
Health Policy
Volume
120
Issue
7
Number of Pages
797-808
Document Type
Article
Personal Identifier
scopus
DOI Link
https://doi.org/10.1016/j.healthpol.2016.05.009
Copyright Status
Unknown
Socpus ID
84975126942 (Scopus)
Source API URL
https://api.elsevier.com/content/abstract/scopus_id/84975126942
STARS Citation
Unruh, Lynn; Rice, Thomas; Rosenau, Pauline Vaillancourt; and Barnes, Andrew J., "The 2013 Cholesterol Guideline Controversy: Would Better Evidence Prevent Pharmaceuticalization?" (2016). Scopus Export 2015-2019. 3613.
https://stars.library.ucf.edu/scopus2015/3613